Hypofibrinogenemia is associated with poor outcome and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome in pediatric severe sepsis

Pediatric Critical Care Medicine

Volumn 19, Issue 5, 2018, Pages 397-405

  Signoff, Jessica K ^a,c   Fitzgerald, Julie C ^b   Teachey, David T ^b   Balamuth, Fran ^b   Weiss, Scott L ^b  

^a University of California at Davis School of Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hemophagocytic lymphohistiocytosis; Hemophagocytic syndrome; Pediatrics; Reactive; Sepsis

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; FIBRINOGEN; METHYLPREDNISOLONE;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPOFIBRINOGENEMIA; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OBSERVATIONAL STUDY; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; ADOLESCENT; AFIBRINOGENEMIA; CASE CONTROL STUDY; COMPLICATION; INFANT; MORTALITY; MULTIPLE ORGAN FAILURE; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; AFIBRINOGENEMIA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MALE; MULTIPLE ORGAN FAILURE; PROGNOSIS; RETROSPECTIVE STUDIES; SEPSIS; YOUNG ADULT;

EID: 85051802641     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0000000000001507     Document Type: Article

References (40)

1. Hartman ME, Linde-Zwirble WT, Angus DC, et al: Trends in the epidemiology of pediatric severe sepsis∗. Pediatr Crit Care Med 2013; 14:686-693
2. Hanna W, Wong HR: Pediatric sepsis: Challenges and adjunctive therapies. Crit Care Clin 2013; 29:203-222
3. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
4. Castillo L, Carcillo J: Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009; 10:387-392
5. Raschke RA, Garcia-Orr R: Hemophagocytic lymphohistiocytosis: A potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest 2011; 140:933-938
6. Okabe T, Shah G, Mendoza V, et al: What intensivists need to know about hemophagocytic syndrome: An underrecognized cause of death in adult intensive care units. J Intensive Care Med 2012; 27:58-64
7. Karapinar B, Yilmaz D, Balkan C, et al: An unusual cause of multiple organ dysfunction syndrome in the pediatric intensive care unit: Hemophagocytic lymphohistiocytosis. Pediatr Crit Care Med 2009; 10:285-290
8. Henter JI, Horne A, Aricó M, et al: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124-131
9. Mehta RS, Smith RE: Hemophagocytic lymphohistiocytosis (HLH): A review of literature. Med Oncol 2013; 30:740
10. Nahum E, Ben-Ari J, Stain J, et al: Hemophagocytic lymphohistiocytic syndrome: Unrecognized cause of multiple organ failure. Pediatr Crit Care Med 2000; 1:51-54
11. Kuwata K, Yamada S, Kinuwaki E, et al: Peripheral hemophagocytosis: An early indicator of advanced systemic inflammatory response syndrome/hemophagocytic syndrome. Shock 2006; 25:344-350
12. Stéphan F, Thiolière B, Verdy E, et al: Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis 1997; 25:1159-1164
13. Strauss R, Neureiter D, Westenburger B, et al: Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients-a postmortem clinicopathologic analysis. Crit Care Med 2004; 32:1316-1321
14. Carcillo JA, Halstead ES, Hall MW, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network Investigators: Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome. Pediatr Crit Care Med 2017; 18:513-523
15. Simon DW, Aneja R, Carcillo JA, et al: Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome∗. Pediatr Crit Care Med 2014; 15:486-488
16. Demirkol D, Yildizdas D, Bayrakci B, et al; Turkish Secondary HLH/MAS Critical Care Study Group: Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatment? Crit Care 2012; 16:R52
17. Henter JI, Chow CB, Leung CW, et al: Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 2006; 367:870-873
18. Sanada S, Ookawara S, Shindo T, et al: A case report of the effect of plasma exchange on reactive hemophagocytic syndrome associated with toxic shock syndrome. Ther Apher Dial 2004; 8:503-506
19. Goto S, Aoike I, Shibasaki Y, et al: A successfully treated case of disseminated tuberculosis-associated hemophagocytic syndrome and multiple organ dysfunction syndrome. Am J Kidney Dis 2001; 38:E19
20. Buyse S, Teixeira L, Galicier L, et al: Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med 2010; 36:1695-1702
21. Allen CE, Yu X, Kozinetz CA, et al: Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50:1227-1235
22. Li F, Yang Y, Jin F, et al: Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: A retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis 2015; 10:20
23. Valade S, Azoulay E, Galicier L, et al: Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore) 2015; 94:e1692
24. Goldstein B, Giroir B, Randolph A: International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8
25. Weiss SL, Fitzgerald JC, Balamuth F, et al: Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 2014; 42:2409-2417
26. Feudtner C, Hays RM, Haynes G, et al: Deaths attributed to pediatric complex chronic conditions: National trends and implications for supportive care services. Pediatrics 2001; 107:E99
27. Pollack MM, Patel KM, Ruttimann UE: PRISM III: An updated Pediatric Risk of Mortality score. Crit Care Med 1996; 24:743-752
28. Slater A, Shann F, Pearson G; Paediatric Index of Mortality (PIM) Study Group: PIM2: A revised version of the Paediatric Index of Mortality. Intensive Care Med 2003; 29:278-285
29. Leteurtre S, Martinot A, Duhamel A, et al: Validation of the paediatric logistic organ dysfunction (PELOD) score: Prospective, observational, multicentre study. Lancet 2003; 362:192-197
30. Voves C, Wuillemin WA, Zeerleder S: International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17:445-451
31. Weiss SL, Cvijanovich NZ, Allen GL, et al: Differential expression of the nuclear-encoded mitochondrial transcriptome in pediatric septic shock. Crit Care 2014; 18:623
32. Wong HR, Weiss SL, Giuliano JS Jr, et al: The temporal version of the pediatric sepsis biomarker risk model. PLoS One 2014; 9:e92121
33. Atkinson SJ, Cvijanovich NZ, Thomas NJ, et al: Corticosteroids and pediatric septic shock outcomes: A risk stratified analysis. PLoS One 2014; 9:e112702
34. Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138:923-936
35. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-823
36. Gando S, Kameue T, Nanzaki S, et al: Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75:224-228
37. Spero JA, Lewis JH, Hasiba U: Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 1980; 43:28-33
38. Ooe K: Pathogenesis of hypofibrinogenemia in familial hemophagocytic lymphohistiocytosis. Pediatr Pathol 1991; 11:657-661
39. Shakoory B, Carcillo JA, Chatham WW, et al: Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial. Crit Care Med 2016; 44:275-281
40. Wong HR, Atkinson SJ, Cvijanovich NZ, et al: Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Crit Care Med 2016; 44:e1000-e1003